JANX

Janux Therapeutics, Inc.

48.03 USD
+0.04 (+0.08%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Janux Therapeutics, Inc. stock is down -1.74% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 May 13:34 17 May, 2024 60.00 CALL 200 1388
08 May 13:38 17 May, 2024 50.00 CALL 72 865
08 May 13:44 17 May, 2024 50.00 CALL 273 865
08 May 13:44 17 May, 2024 50.00 CALL 52 865
08 May 13:44 17 May, 2024 50.00 CALL 44 865
08 May 13:44 17 May, 2024 50.00 CALL 59 865
08 May 14:15 21 Jun, 2024 55.00 PUT 100 299
13 May 17:38 21 Jun, 2024 50.00 CALL 100 16
13 May 17:58 17 May, 2024 50.00 CALL 364 521
20 May 16:41 21 Jun, 2024 50.00 CALL 201 223

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. The company was incorporated in 2017 and is headquartered in La Jolla, California.

  • HC Wainwright & Co.
    Mon May 13, 07:17
    buy
    confirm
  • Cantor Fitzgerald
    Thu May 9, 10:18
    buy
    confirm
  • Wedbush
    Wed May 8, 10:41
    buy
    confirm